Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.73 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.73 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.73 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | CCR6 | P51684 | 1/20 | 0.67 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | DDX3X | O00571 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794156 | 1.00 | MEN1 (0.73) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL23547197 | 0.85 | TRPV1 (0.73) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL6754378 | 0.85 | TRPV1 (0.73) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL6754380 | 0.85 | TRPV1 (0.73) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL27746161 | 0.83 | KMT2A (0.66) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL441804 | 0.82 | LPAR2 (1.00) | MEN1KMT2AMAPTALDH1A1LPAR1 | |
| SCHEMBL441805 | 0.82 | LPAR2 (1.00) | MEN1KMT2AMAPTALDH1A1LPAR1 | |
| SCHEMBL1552033 | 0.82 | LPAR2 (1.00) | MEN1KMT2AMAPTALDH1A1LPAR1 | |
| SCHEMBL5149342 | 0.82 | KMT2A (0.69) | MEN1KMT2AMAPTALDH1A1HSP90AA1 | |
| SCHEMBL468012 | 0.82 | KMT2A (0.68) | MEN1KMT2AMAPTALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0403240-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-08-24 | — | — | EP | claimed |
| EP-0372922-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-03-09 | — | — | EP | claimed |
| US-5175309-A | Forming an imide by heat catalytic dehydration | MITSUI TOATSU CHEMICALS INC. (JP) | 1992-12-29 | — | — | US | claimed |
| US-5068357-A | Heat dehydration of an N-substituted maleamic acid with a solvent, distillation after imidation, in the presence of a tin catalyst | MITSUI TOATSU CHEMICALS, INC. (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0403240-A1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-12-19 | — | — | EP | claimed |
| EP-0372922-A2 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-13 | — | — | EP | claimed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| EP-0403240-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-08-24 | — | — | EP | disclosed |
| EP-0372922-B1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS (JP) | 1994-03-09 | — | — | EP | disclosed |
| US-5175309-A | Forming an imide by heat catalytic dehydration | MITSUI TOATSU CHEMICALS INC. (JP) | 1992-12-29 | — | — | US | disclosed |
| US-5068357-A | Heat dehydration of an N-substituted maleamic acid with a solvent, distillation after imidation, in the presence of a tin catalyst | MITSUI TOATSU CHEMICALS, INC. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0403240-A1 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-12-19 | — | — | EP | disclosed |
| EP-0372922-A2 | Preparation process of N-substituted maleimides | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | MEN1 2703/4885KMT2A 968/4885MAPT 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.